Our key takeaways…
Thanks for reading! Subscribe for free to receive new posts and support my work.
1.The COVID Hangover Is (Finally) Over
The 2020 biotech bubble flooded the sector with too much money, financing low-quality companies at inflated valuations. Four years later, the market has finally reset. Companies that needed to fail have failed, and investors can actually make money again.
2. AI in Drug Development: Useful, But Not a Magic Bullet
AI is cutting drug design timelines and streamlining regulatory applications. But there’s still no substitute for clinical trials and putting drugs into actual human beings. Digital twins and side effect predictions are helpful, but they’re still a “murky crystal ball.”
3. China Is No Longer Just Our CRO — They’re Our Competition
China started doing contract work for Western companies. Now they’re developing best-in-class drugs and running clinical trials faster than the US. In 20 years, Chinese pharma companies will be major global players.
4. Brain Drain Is the Real Threat Nobody’s Talking About
The US leads in biotech because we have the best talent — trained through NIH-funded programs. But faculty members are already being recruited to leave, particularly in infectious disease and vaccine development. If we lose the talent pool, we lose the industry.
5. States Can’t Replace NIH Funding
When you cut NIH funding, you don’t see the impact for 5, 10, or 15 years — but you will feel it. States simply don’t have the firepower to fill the gap. There is no substitute for NIH.
6. What Gets Investors to Say Yes: Proof of Concept
Investors want one thing: proof of concept. Don’t get distracted chasing “platform company” pitches or spreading yourself thin across multiple indications. Focus on that singular endpoint and run like hell — without spending too much money along the way.
7. The #1 Red Flag That Kills Deals: Defensiveness
Shit happens. Trials fail. Regulatory outcomes disappoint. The difference between repeat winners and repeat losers? Intellectual honesty — founders who can discuss their mistakes without being defensive.
